Febuxostat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PHARMAC (New Zealand) and SMC (Scotland) recommended or restricted febuxostat, while AWMSG (Wales) and PBAC (Australia) did not recommend it.
The file has been open for more than a decade: 16.5 years separate the first record, 24 Jun 2009 at HAS (France), from the most recent, 17 Dec 2025 at HAS (France).
TLV (Sweden) changed its position: not recommended on 25 May 2016, restricted by 3 Oct 2017, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
5 distinct indication wordings are recorded for febuxostat by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess febuxostat, on 24 Jun 2009; TLV (Sweden) did not open a file until 25 May 2016 — a wide spread of 6.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
Restriction is doing real work here: 3 of 12 decisive outcomes narrowed febuxostat to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
5 of the 6 agencies here assessed febuxostat more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for febuxostat.
The full ledger for febuxostat reads 5 recommended, 4 not recommended, 3 restricted and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 14 Aug 2020 | Prevention of tumour lysis syndrome (TLS) in allopurinol-intolerant patients scheduled to receive a cancer therapy that … | PTAC advice: High · decision reached | source |
| TLV (Sweden) | 3 Oct 2017 | Adenuric ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| PBAC (Australia) | 2017 | Chronic gout | The PBAC did not recommend amending the current Authority Required listing of febuxostat f… | source |
| SMC (Scotland) | 13 Jun 2016 | for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Sy… | accepted (restricted) | source |
| HAS (France) | 24 Jun 2009 | Listing (Transparency Committee) | ASMR IV | source |
8 further decisions for febuxostat, across 6 agencies, are not shown here. They include the most recent record on file, 17 Dec 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- cefazolin — also decided by HAS in 2025Q4
- ibrutinib — also decided by HAS in 2025Q4
- lisocabtagene maraleucel — also decided by HAS in 2025Q4
- mirdametinib — also decided by HAS in 2025Q4
- iptacopan — also decided by HAS in 2025Q4
- etonogestrel — also decided by HAS in 2025Q4
Coverage: 13 decisions for febuxostat from 6 agencies, 2009 to 2025. Data to 7 Sep 2026. ATC class M04A — Antigout. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.